CASI Pharmaceuticals, Inc. SEC filings CASIF
CASI Pharmaceuticals, Inc. has 157 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 2, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | May 15, 2026 | Dec 31, 2025 |
| 20-F | Annual report (foreign issuer) | Mar 31, 2025 | Dec 31, 2024 |
| 20-F | Annual report (foreign issuer) | Mar 28, 2024 | Dec 31, 2023 |
| 20-F | Annual report (foreign issuer) | Apr 26, 2023 | Dec 31, 2022 |
Showing 4 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CASIF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Beijing, China
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1962738
- Former names
- CASI Pharmaceuticals Holdings, Inc. (until Feb 14, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.